t:slim Control-IQ and Dexcom G6
Predicts and helps prevent highs and lows
†If your glucose alerts and readings from Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
Did you know the Dexcom G6 Continuous Glucose Monitoring is subsidised for all Australians living with type 1 diabetes? Find out more here.

How does Control-IQ™ Technology work?

Have you heard of our loan programs?

At AMSL Diabetes, we strive to complement patient freedom and remove barriers to access to advanced diabetes management technology. We're excited to introduce two tailored loan streams for t:slim X2 insulin pump, aimed at supporting early initiation and flexible management for Type 1 diabetes patients.

P16_SR100756_Tandem_Scene_3_Shot_5-0015_give it a try 2

Give it a Try

The Give it a Try initiative allows a two-month trial with the t:slim X2 insulin pump, subject to application approval and certain conditions. It provides an opportunity for individuals to experience the pump's benefits first hand.

Key features
For anyone with Type 1 Diabetes to trial pump therapy. Does not require Private Health Insurance.

Get in touch with us for more information or to find out how to apply.

Contact us

Accelerate & Pump

Accelerate & Pump

Don't wait for health insurance to mature, loan a t:slim X2 insulin pump through the AMSL Diabetes Accelerate & Pump program. 

Key features
For those awaiting maturity of Private Health Insurance. 

Get in touch with us for more information or to find out how to apply.

Contact us


Interested in Control-IQ Technology?

Fill in the form below and one of our representatives will be in touch regarding the t:slim X2 pump, and to help answer your questions!

**Additional feature updates are subject to future regulatory approvals. Control-IQ technology is not a substitute for active self-management of your diabetes. Control-IQ technology is only available with Dexcom G6 CGM. Dexcom G6 CGM sold separately.

1. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al. Predictive low-glucose suspend reduces hypoglycaemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial. Diabetes Care. 2018;41(10):2155-2161. doi:10.2337/dc18-0771.

Back to top